Lenvatinib, another VEGFR and FGFR inhibitor, was able to reverse the immunosuppressive effect mediated by growth factors and synergized with anti-PD-1 antibody in a colon cancer model. This evidence concerns the gene PDCD1 and malignant colon neoplasm.